AstraZeneca Plc (LON:AZN) today provided an results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial. Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial..

AstraZeneca plc (LON:AZN) has completed the acquisition of Neogene Therapeutics Inc., a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts). Neogene will..

AstraZeneca plc (LON:AZN) and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the European Union for the treatment of metastatic castration-resistant prostate cancer..

AstraZeneca plc (LON:AZN) and MSD today announced that the US Food and Drug Administration (FDA) has informed AstraZeneca that it will extend the Prescription Drug User Fee Act (PDUFA) date..

AstraZeneca plc (LON:AZN) has announced the sale of its West Chester site in Ohio, US, to National Resilience, Inc., a technology-focused manufacturing company dedicated to broadening access to complex medicines...

AstraZeneca plc (LON:AZN) Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer..

AstraZeneca plc (LON:AZN) Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with Stage IV (metastatic) non-small..

AstraZeneca plc (LON:AZN) has announced that PT027 has been recommended by FDA advisory committee as new rescue treatment for asthma. The Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee..

Positive high-level results from the CAPItello-291 Phase III trial showed that AstraZeneca plc (LON:AZN) capivasertib in combination with Faslodex (fulvestrant) demonstrated a statistically significant and clinically meaningful improvement in progression-free..

AstraZeneca plc (LON:AZN) has announced that Ultomiris (ravulizumab) has been approved in Europe as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG)..

AstraZeneca plc (LON:AZN) and Sanofi’s Beyfortus (nirsevimab) has been recommended for marketing authorisation in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease..

AstraZeneca plc (LON:AZN) Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney..

Detailed results from the DELIVER Phase III trial showed AstraZeneca plc (LON:AZN) Farxiga (dapagliflozin) significantly reduced the composite of cardiovascular (CV) death or worsening heart failure (HF) in patients with..

AstraZeneca plc (LON:AZN) supplemental New Drug Application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for..

AstraZeneca plc (LON:AZN) has announced that positive high-level results from the DESTINY-Breast02 Phase III trial of Enhertu (trastuzumab deruxtecan) versus physician’s choice of treatment showed the trial met the primary..

AstraZeneca plc (LON:AZN) has completed the acquisition of TeneoTwo, Inc.i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.1 AstraZeneca..

AstraZeneca plc (LON:AZN) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC..

AstraZeneca plc (LON:AZN) and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients..